治疗性白介素-6阻断逆转系统性硬化症真皮成纤维细胞中转化生长因子-β通路活化:来自faSScinate临床试验的启示
研究利用faSScinate试验中12例系统性硬化症患者(安慰剂组6例、托珠单抗组6例)基线与第24周配对皮肤活检培养的成纤维细胞,分析其分子、功能与基因组特征。结果显示安慰剂组成纤维细胞的活化表型24周内稳定,而托珠单抗治疗24周使成纤维细胞功能正常化并逆转以转化生长因子-β调控基因为主的表达谱。
要点
- 安慰剂组系统性硬化症成纤维细胞的活化表型在24周内保持稳定。
- 托珠单抗治疗24周使离体真皮成纤维细胞功能特性正常化并逆转转化生长因子-β调控基因表达谱。
- 白介素-6受体阻断对活化成纤维细胞表型的显著影响提示白介素-6是系统性硬化症及其他纤维化疾病的潜在治疗靶点。
核心结论
- 利用设计良好的系统性硬化症试验中离体真皮成纤维细胞培养,建立了连接白介素-6与关键促纤维化通路的分子框架。
- 白介素-6受体阻断对活化成纤维细胞表型的显著影响提示白介素-6是系统性硬化症及其他纤维化疾病的潜在治疗靶点。
研究设计与样本
- 分析faSScinate研究中12例系统性硬化症患者基线与第24周配对皮肤活检培养的离体成纤维细胞的分子、功能与基因组特征,其中安慰剂组6例、托珠单抗组6例,并与匹配的健康对照成纤维细胞株比较。
- 患者接受托珠单抗(白介素-6受体α抑制剂)治疗24周。
- 试验注册号NCT01532869。
主要发现
- 在系统性硬化症样本中定义了标志性功能与分子活化表型,该表型在安慰剂治疗病例中24周内保持稳定。
- RNA测序分析稳健地定义了可能驱动系统性硬化症成纤维细胞体内活化的关键失调通路。
- 托珠单抗治疗24周通过使功能特性正常化并逆转以转化生长因子-β调控基因和分子通路为主的基因表达谱,深刻改变了离体真皮成纤维细胞的生物学特征。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Skin fibrosis mediated by activated dermal fibroblasts is a hallmark of systemic sclerosis (SSc), especially in the subset of patients with diffuse disease. Transforming growth factor-beta (TGFβ) and interleukin-6 (IL-6) are key candidate mediators in SSc. Our aim was to elucidate the specific effect of IL-6 pathway blockade on the biology of SSc fibroblasts in vivo by using samples from a unique clinical experiment-the faSScinate study-in which patients with SSc were treated for 24 weeks with tocilizumab (TCZ), an IL-6 receptor-α inhibitor. METHODS: We analysed the molecular, functional and genomic characteristics of explant fibroblasts cultured from matched skin biopsy samples collected at baseline and at week 24 from 12 patients receiving placebo (n=6) or TCZ (n=6) and compared these with matched healthy control fibroblast strains. RESULTS: The hallmark functional and molecular-activated phenotype was defined in SSc samples and was stable over 24 weeks in placebo-treated cases. RNA sequencing analysis robustly defined key dysregulated pathways likely to drive SSc fibroblast activation in vivo. Treatment with TCZ for 24 weeks profoundly altered the biological characteristics of explant dermal fibroblasts by normalising functional properties and reversing gene expression profiles dominated by TGFβ-regulated genes and molecular pathways. CONCLUSIONS: We demonstrated the exceptional value of using explant dermal fibroblast cultures from a well-designed trial in SSc to provide a molecular framework linking IL-6 to key profibrotic pathways. The profound impact of IL-6R blockade on the activated fibroblast phenotype highlights the potential of IL-6 as a therapeutic target in SSc and other fibrotic diseases. TRIAL REGISTRATION NUMBER: NCT01532869; Post-results.
引用
- Denton CP, Ong VH, Xu S, et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann Rheum Dis. 2018. PMID: 29853453. doi:10.1136/annrheumdis-2018-213031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。